BioCardia, Inc. cotiza a 1.02 USD y tiene una capitalización bursátil de $15M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment o…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.21 | $-0.06 | $-0.24 | $-0.40 |
| Estimado | $-0.17 | $-0.20 | $-0.25 | $-0.50 |
| Sorpresa | -23.5% | +70.0% | +4.0% | +20.0% |
| Métrica | BCDA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -919.3% | -40.4% | -878.9% |
| ROA | -241.1% | -32.0% | -209.1% |
| Current Ratio | 1.12 | 2.84 | -1.72 |
| Debt / Equity | — | 0.28 | — |